BIPHETAMINE 7.5
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 7.5 is a brand-name amphetamine product in extended-release capsule form approved in 1955 by UCB Pharma. The specific mechanism of action and approved indications are not publicly detailed in available data, but amphetamines are CNS stimulants typically used for attention and wakefulness disorders. This is a legacy small-molecule product with a long commercial history.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential downsizing of commercial teams and shift to defensive positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BIPHETAMINE 7.5 offers limited career growth given zero linked job openings and approaching LOE status. Professionals on this product should expect consolidation and may benefit from transitioning to growth-stage assets within UCB's portfolio.
Brand ManagerField Sales Representative
Worked on BIPHETAMINE 7.5 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.